Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib versus placebo in radioiodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy
NL-OMON52807Phase 3Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) and thyroid cancer comparing Cabozantinib with Placebo (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Started Dec 2019; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON52807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52807.